Chimeric Protein Suppressing Cryptic Exons in TDP-43 Pathology
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of TDP-43 proteinopathy in ALS and FTD is limited, particularly how TDP-43 contributes to neurodegeneration, and existing methods fail to effectively address the dysregulation of TDP-43, which is central to the pathogenesis of these diseases.
Innovation Solution
A method involving the detection of TDP-43 dysregulation using immunoassays or nucleic acid probes and the administration of a chimeric protein comprising an N-terminal domain of TDP-43 and a splicing repressor domain to suppress cryptic exons, which are associated with TDP-43 proteinopathy, using vectors like adenovirus or lentivirus for gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TDP-43 binds to distal introns to suppress cryptic exons, then mRNA integrity is maintained and cell survival is supported, but TDP-43 nuclear clearance occurs leading to proteinopathy
Solution Approach 1:
The patent extracts and identifies the specific function of TDP-43 binding to distal introns to suppress cryptic exons, separating this physiological function from the pathological nuclear clearance process. By pinpointing the precise location and mechanism of TDP-43's protective action, the patent enables targeted therapeutic strategies that preserve this function while addressing the harmful proteinopathy.
Solution Approach 2:
The patent introduces distal introns as an intermediary element that mediates between TDP-43 and cryptic exons. TDP-43 binds to these intronic regions to suppress cryptic exon splicing, acting as a protective intermediary that prevents harmful mRNA processing while maintaining nuclear TDP-43 levels and preventing proteinopathy.
2Object-generated harmful factors
If TDP-43 clears from the nucleus, then cytoplasmic inclusions form, but this reflects loss-of-function and contributes to neurodegeneration
Solution Approach 1:
The patent converts the harmful effect of TDP-43 nuclear clearance into a beneficial understanding by identifying that the clearance process itself is the problem. The patent shows that maintaining TDP-43 in the nucleus through cryptic exon suppression prevents the harmful cytoplasmic inclusions and neuronal degeneration, turning the loss-of-function hypothesis into a therapeutic target.
3Reliability
If cryptic exons are suppressed, then cell death is reversed, but this requires targeted intervention in splicing regulation
Solution Approach 1:
The patent segments the splicing regulation mechanism into specific components: TDP-43 binding to distal introns, suppression of cryptic exons, and prevention of mRNA degradation. This segmentation allows for targeted therapeutic intervention at specific steps in the splicing pathway, reducing the complexity of overall splicing regulation while maintaining cell survival.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively detects TDP-43 dysregulation and treats or prevents diseases like ALS and FTD by suppressing cryptic exons, thereby rescuing cell death and maintaining cellular integrity, offering a promising therapeutic strategy for these neurodegenerative disorders.
Implementation Method 1
a chimeric protein comprising an N-terminal domain of TDP-43 and a splicing repressor domain to suppress cryptic exons
Implementation Method 2
testing the biological sample with an immunoassay based on an antibody or antibodies raised against one or more protein translated from one or more cryptic exons
Data Source
AI summary
Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).